tryz, operating in 40 States is something I don't think most investors can grasp as to what's ahead in terms of potential revenues and profit. I'm in the pharma industry and really can't get a handle on it. The reason is because SCRC is so diversified right now due to Mr. Schneiderman's business brilliance. I know right now everyone thinks of SCRC as MAV compounding but by the end of 2015 investors won't recognize this company. I still maintain 2015 is the explosion year for SCRC and overcoming this Caremark challenge will demonstrate the strength of the organization. The current pps will be merely a memory in the months to follow.